Janssen Korea to launch Velcade, a new cancer drug.

Published: 2004-09-06 06:58:00

Updated: 2004-09-06 06:58:00

Janssen Korea announced that an anti-cancer drug of new mode of action, Velcade (bortezomib) injection, would be launched from Sept. 1 for the treatment of multiple myeloma. Velcade is the new anti-cancer drug by irreversibly blocking the activity of proteazome, a protease of breaking the protein...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK